Colorectal cancer (CRC) is one of the most common malignancies worldwide.1KRAS mutations are observed in approximately 45% of CRC cases and are clinically associated with tumor invasion and metastasis, resistance to therapy, and a poor overall survival.2–4 The most common sites of oncogenic KRAS mutations are codons 12, 13, 61, 117, and 146. This evidence concerns the gene KRAS and colorectal cancer.